MONEY

Merck's KEYTRUDA ® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 00:00
Merck's KEYTRUDA ® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Read More

Tags:

Previous Article

Iran says it is open to talks but rejects pressure as US, EU impose sanctions

Next Article

Abbot Schröder elected Abbot Primate of Benedictine Confederation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

K1 to Exit Axcient, a Category Leader in Business Continuity and Disaster Recovery Solutions

K1 to Exit Axcient, a Category Leader in Business Conti...

Tomas Kauer - Mode... Sep 11, 2024

Asset entities Inc. executive sells over $470k in company stock

Asset entities Inc. executive sells over $470k in compa...

Tomas Kauer - Mode... Sep 17, 2024

Pacific leaders remove Taiwan from communique after China complaint

Pacific leaders remove Taiwan from communique after Chi...

Tomas Kauer - Mode... Sep 1, 2024